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+kinase NAD salvage pathway in a model
of sarcoplasmic reticulum dysfunction
Craig L. Doig1,2, Agnieszka E. Zielinska1, Rachel S. Fletcher1,2, Lucy A. Oakey1,2, Yasir S. Elhassan1,2, Antje Garten1,
David Cartwright1,2, Silke Heising1,2, Ahmed Alsheri3, David G. Watson3, Cornelia Prehn4,5,6, Jerzy Adamski4,5,6,
Daniel A. Tennant1,2 and Gareth G. Lavery1,2,7*Abstract
Background: Hexose-6-Phosphate Dehydrogenase (H6PD) is a generator of NADPH in the Endoplasmic/
Sarcoplasmic Reticulum (ER/SR). Interaction of H6PD with 11β-hydroxysteroid dehydrogenase type 1 provides
NADPH to support oxo-reduction of inactive to active glucocorticoids, but the wider understanding of H6PD in ER/
SR NAD(P)(H) homeostasis is incomplete. Lack of H6PD results in a deteriorating skeletal myopathy, altered glucose
homeostasis, ER stress and activation of the unfolded protein response. Here we further assess muscle responses to
H6PD deficiency to delineate pathways that may underpin myopathy and link SR redox status to muscle wide
metabolic adaptation.
Methods: We analysed skeletal muscle from H6PD knockout (H6PDKO), H6PD and NRK2 double knockout (DKO)
and wild-type (WT) mice. H6PDKO mice were supplemented with the NAD+ precursor nicotinamide riboside.
Skeletal muscle samples were subjected to biochemical analysis including NAD(H) measurement, LC-MS based
metabolomics, Western blotting, and high resolution mitochondrial respirometry. Genetic and supplement models
were assessed for degree of myopathy compared to H6PDKO.
Results: H6PDKO skeletal muscle showed adaptations in the routes regulating nicotinamide and NAD+
biosynthesis, with significant activation of the Nicotinamide Riboside Kinase 2 (NRK2) pathway. Associated with
changes in NAD+ biosynthesis, H6PDKO muscle had impaired mitochondrial respiratory capacity with altered
mitochondrial acylcarnitine and acetyl-CoA metabolism. Boosting NAD+ levels through the NRK2 pathway using the
precursor nicotinamide riboside elevated NAD+/NADH but had no effect to mitigate ER stress and dysfunctional
mitochondrial respiratory capacity or acetyl-CoA metabolism. Similarly, H6PDKO/NRK2 double KO mice did not
display an exaggerated timing or severity of myopathy or overt change in mitochondrial metabolism despite
depression of NAD+ availability.
Conclusions: These findings suggest a complex metabolic response to changes in muscle SR NADP(H) redox status
that result in impaired mitochondrial energy metabolism and activation of cellular NAD+ salvage pathways. It is
possible that SR can sense and signal perturbation in NAD(P)(H) that cannot be rectified in the absence of H6PD.
Whether NRK2 pathway activation is a direct response to changes in SR NAD(P)(H) availability or adaptation to
deficits in metabolic energy availability remains to be resolved.
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Our understanding of the control of NADP(H) redox
homeostasis within muscle sarcoplasmic reticulum (SR)
and its influence over cellular metabolism is developing
[1–4]. A major enzyme that reduces NADP+ within the
SR lumen is hexose-6-phosphate dehydrogenase (H6PD)
which oxidises glucose-6-phosphate derived from gly-
colysis to generate NADPH [5, 6]. A known function of
H6PD is its physical interaction with 11β-hydroxysteroid
dehydrogenase type 1 (11β-HSD1) in the SR lumen [7].
H6PD NADPH generation supports 11β-HSD1 oxo-
reductase activity for glucocorticoid production [3]. The
importance of the H6PD-11β-HSD1 interaction is clear
in humans with ‘apparent’ cortisone reductase deficiency
(ACRD) due to inactivating mutations in the H6pd gene
[8, 9]. In ACRD, the lack of H6PD and its associated
NADPH production switches 11β-HSD1 activity towards
glucocorticoid oxidation (and therefore NADP+ reduc-
tion) resulting in increased tissue glucocorticoid clear-
ance and relative insensitivity. Affected individuals
manifest disease as a function of increasing
hypothalamic-pituitary-adrenal axis activity and resultant
excess adrenal androgen production [10]. H6PD knock-
out (H6PDKO) mice reflect this biochemistry, manifest-
ing an ACRD-like phenotype, showing tissue
glucocorticoid insensitivity and HPA axis activation [6].
Liver and adipose tissues demonstrate phenotypes asso-
ciated with relative glucocorticoid insensitivity. The liver
has impaired ability to stimulate gluconeogenesis, with
increased glycogen synthesis rates, while adipose tissue
has impaired ability to store and mobilise lipid [11, 12].
Skeletal muscle of H6PD knockout mice develop a
progressively deteriorating myopathy associated with
large intrafibrillar membranous vacuoles, abnormal
sarcoplasmic reticulum (SR) structure, dysregulated ex-
pression of SR proteins involved in calcium metabolism
and switching of type II to type I fibers and impaired
force generation [4]. Associated with myopathy is ER
stress and activation of the unfolded protein response-
partially attributed to altered SR lumen protein folding
capacity [2, 4]. Metabolically H6PDKO demonstrate dys-
function in glucose homeostasis, characterised by fasting
hypoglycaemia, increased skeletal muscle insulin sensi-
tivity (particularly in type II fibre-rich muscles) and in-
creased glycogen content [4, 13]. Importantly, H6PDKO
myopathy is independent of the role of 11β-HSD1 and
glucocorticoids [13].
It has been proposed that H6PD contributes to ER/SR
redox balance beyond regulation of 11β-HSD1 activity.
This is evident through both its effects on physiological
glucose metabolism, as well as adrenal steroidogenic en-
zyme activity [14]. Less clear is the interaction and con-
tribution of H6PD and ER/SR NADP(H) to whole cell
redox and cellular energy metabolism. The major sourceof cellular NADPH is reduction of NADP+ through the
pentose phosphate pathway, with NADP+ synthesised
from NAD+ via NAD+ kinase [15]. While muscle has the
capacity to co-opt multiple pathways for NAD(P)(H)
biosynthesis, it largely relies on salvage of vitamin B3
precursors, chiefly nicotinamide (NAM) which can be
recycled back to NAD+ via NAM phosphoribosyltrans-
ferase [16].
We wanted to investigate primary pathways respond-
ing to the perturbations in SR NADP(H) redox due to
H6PD deficiency using unbiased and targeted metabolo-
mics and existing transcriptional data [4]. We show that
in young mice, prior to overt phenotypic presentation,
H6PDKO remodels NAD(P)(H) biosynthesis, particularly
through the nicotinamide riboside kinase 2 (NRK2)
pathway. H6PD deficiency also results in upregulation of
pathways to acetyl-CoA production leading to accumula-
tion of short chain acylcarnitines, elevated acetylation of
mitochondrial proteins and impaired mitochondrial fatty
acid oxidation. Acetylation of the mitochondrial prote-
ome is associated with depression in energy production,
and can be countered through the activity of the NAD+-
dependent deacetylase SIRTs [17, 18]. Taking advantage
of elevated NRK2 expression we augmented NAD+ avail-
ability in H6PDKO mice by supplementing the precursor
nicotinamide riboside (NR). Similarly H6PD/NRK2
double KO mice were examined as a means to further
limit NAD+ availability. While each approach was able
to modulate NAD+ metabolism, neither was able to res-
cue or exacerbate mitochondrial dysfunction or myop-
athy. These findings reveal a complex metabolic
response to changes to muscle SR NADP(H) redox sta-
tus and associated impairment in mitochondrial energy
metabolism.
Materials and methods
Animal care, mouse strains, storage
All mice (C57/BL6J background) were group housed ac-
cording to sex in a standard temperature (22 °C) and
humidity-controlled environment with 12:12-h light:dark
cycle. Nesting material was provided and mice had ad
libitum access to water and standard chow. This study
used global knockout of H6PD, these phenocopy muscle
specific knockout mice [13, 19]. Studies used both male
and female mice. During the generation of data there
were no sex specific differences observed. Mice were
sacrificed using schedule one cervical dislocation Collec-
tions were all performed at 10-11 am. For collection of
serum, murine blood was obtained by cardiac puncture
and immediately centrifuged at 1000 x g in heparin-
coated tubes. Serum was transferred to cryotubes and
snap-frozen.
Nicotinamide riboside chloride was resuspended in
phosphate buffered saline (PBS) and sterile filtered.
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peritoneal injections of Nicotinamide Riboside (400mg/
kg) were given twice daily, (10 am and 3 pm) for 4 days
before cervical dislocation and skeletal muscle bed col-
lection on Day 5 (10 am), tissues were flash frozen, fixed
or for high resolution respirometry stored in BIOPS buf-
fer. Heterozygotes of H6PDKO and NRK2KO were bred
to generate H6PD-NRK2 KO mice. Mice were utilised
between 8 and 12 weeks of age. Experiments were con-
sistent with current UK Home Office regulations in ac-
cordance with the UK Animals Scientific Procedures Act
1986.
RNA extraction and qRT-PCR
Total RNA was extracted from skeletal muscle tissue
using TRI-reagent (Invitrogen). RNA quality was deter-
mined by visualisation on a 1.5% agarose gel and quan-
tity was measured by nanodrop absorbance at 260 nm.
Reverse transcription was conducted using 1 μg RNA
not DNAse treated that was incubated with 250uM ran-
dom hexamers, 5.5 mM MgCl2, 500uM dNTPs, 20 units
RNase inhibitor 63 units multi-scribe reverse transcript-
ase and 1x reaction buffer. Reverse transcription was
performed on a thermocycler set at the following condi-
tions: 25 °C 10min, 48 °C for 30 min before the reaction
was terminated by heating to 98 °C for 5 min. cDNA
levels were determined using an ABI7500 system (Ap-
plied Biosystems), reactions were conducted in a 384-
well plate in single-plex format. Primers and probes were
purchased as Assay on Demand (FAM) products (Ap-
plied Biosystems), predesigned to cross exon boundaries
to preclude genomic DNA measurement. Total reaction
volumes used were 10ul containing Taqman Universal
PCR mix (Applied Biosystems). All reactions were nor-
malised to 18 s rRNA (VIC) (Applied Biosystems). The
real-time PCR reaction was performed at the following
conditions: 95 °C for 10 min then 40 cycles of 95 °C for
15 s and 60 °C for 1 min. Data were collected as Ct
values and used to obtain deltaCt (dCt) values and
expressed as fold change ±standard error of the mean
(SEM).
Mitochondrial DNA (mtDNA) copy number
DNA was isolated using phenol-chloroform and washed
in Ethanol before quantification using nanodrop. DNA
from all samples was diluted to 50 ng/μl and subject to
real-time PCR using SYBRgreen master mix (Applied
Biosystems) using the following primers specific for nu-
clear and mitochondrial DNA.
Nuclear DNA: TERT Forward CTAGCTCATGTGTC
AAGACCCTCTT Reverse GCCAGCACGTTTCTCTCG
TT, Mitochondrial DNA: DLOOP Forward AATCTA
CCATCCTCCGTGAAACC Reverse TCAGTTTAGC
TACCCCCAAGTTTAA, ND4 Forward AACGGATCCACAGCCGTA Reverse AGTCCTCGGGCCAT
GATT.
Western blotting
Protein lysates were collected in RIPA buffer (50 mmol/l
Tris pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 150
mmol/l NaCl, 1 mmol/l EDTA), protease & phosphatase
inhibitor cocktail (Roche, Lewes, U.K.), stored at − 80 °C
(> 30min), defrosted on ice and centrifuged at 4 °C
(10mins, 12,000 rpm). The supernatant was recovered
and total protein concentration was assessed by Bio-Rad
assay. Total proteins were resolved on a 12% SDS-PAGE
gel and transferred onto a nitrocellulose membrane. Pri-
mary antibodies; Anti-Goat H6PD (in house), Anti-
Mouse NAMPT (Bethyl A300-372A), Anti-Rabbit NRK1
(in house [20]), Anti-Rabbit NRK2 (in house), Anti-
Rabbit CHOP (Cell Signaling D46F1 5554), Total Lysine
Ac (Cell Signaling 9441), Anti-Mouse Rodent OXPHOS
Mitoprofile (Abcam ab110413), IDH2 K413 ac (GeneTel
AC0004), IDH2 Total (Abcam ab55271), H3K9ac (Cell
Signaling 9649), H3K56ac (Cell Signaling 4243), ERO1a
(Cell Signaling 3264), PDI (Cell Signaling 3501), alpha-
Tubulin (Santa Cruz B-7 sc-5286). Secondary antibodies
(Dako) anti-mouse, anti-goat and anti-rabbit conjugated
with HRP added at a dilution of 1/10,000. Equal loading
of protein content was verified using alpha-tubulin as a
housekeeping protein and bands visualised using ECL
detection system (GE Healthcare, UK). Bands were mea-
sured using Image J densitometry, and normalised to
those of loading control (alpha tubulin).
High-resolution respirometry of permeabilised muscle
fibres by Oroboros
Respirometry studies in tibialis anterior (TA) and soleus
(SOL) skeletal muscle myofibres were performed using
high-resolution respirometry (Oroboros Instruments,
Innsbruck, Austria). Fresh skeletal muscle (5 mg) was
stored in ice-cold 2mls BIOPS buffer. Any connective
tissue and adipose was discarded and 20 μl of Saponin
stock solution for permeabilisation of muscle fibres (5
mg Saponin per ml BIOPS buffer) added. The samples
were then incubated for 30 min at 4 °C. Muscles were
washed in Mir05 for 10 min at 4 °C before drying on fil-
ter paper. Approximately 3mgs of muscle tissue was in-
troduced into the chamber and left for > 10 min to give
a stable baseline signal, re-oxygenation occurred once
O2 concentration reached 250 μM. Sequential addition
of inhibitors and substrates occurred as per Oroboros
Instruments specified protocol for fatty acid oxidation.
NAD+ quantification by colorimetric assay
NAD+ was extracted from flash frozen skeletal muscle
and NAD+/NADH quantified using the NAD+/NADH
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turers instructions.Untargeted metabolomic measurement
Twenty milligrams of skeletal muscle previously flash
frozen tissue from TA or SOL was placed in dry ice. Me-
tabolites were extracted into 0.5 ml of ice-cold LC-MS
grade methanol:acetonitrile:water (50:30:20). Samples
were pulverised and stored at 4 °C for 10 min before cen-
trifugation at 0 °C 1300 rpm for 15 min. Supernatant was
then transferred to HPLC vials ready for LC-MS ana-
lysis. To preclude variables introduces from preparing
samples separately all samples were prepared simultan-
eously in a randomised order and re-randomised before
injection in the LC-MS. Untargeted metabolomics was
carried out by using an Accela HPLC system interfaced
to an Exactive Orbitrap mass spectrometer (Thermo
Fisher Scientific, Bremen, Germany) was used for the li-
quid chromatographic separations. ZIC-pHILIC (150 ×
4.6 mm, 5 μm) HPLC column supplied by HiChrom
(Reading, UK) were used. Samples were run on LC-MS
under the following conditions: the ZIC-pHILIC mobile
phase consisted of 20 mM ammonium carbonate in
HPLC-grade water (A) and acetonitrile (B); the solvent
gradient used was 80% B (0 min), 20% (30 min), 8% (31–
36min), and 80% (37–45 min) at a flow rate of 0.3 mL/
min. The nitrogen sheath and auxiliary gas flow rates
were maintained at 50 and 17 arbitrary units. The elec-
trospray ionisation (ESI) interface was employed in a
positive/negative dual polarity mode, with a spray volt-
age of 4.5 kV for positive mode and 4.0 kV for negative
mode, while the ion transfer capillary temperature was
set at 275 °C. Full scan data were obtained in the mass-
to-charge ratio (m/z) between 75 and 1200 amu for both
ionisation modes. The data were collected and processed
using Xcalibur 2.1.0 software (Thermo Fisher Scientific,
Bremen, Germany). Data Extraction and Statistical Ana-
lysis The data were extracted using MZMatch software
(SourceForge, La Jolla, USA). A macro-enabled Excel
Ideom file was used to filter, compare and identify the
metabolites. The metabolite lists obtained from these
searches were then carefully evaluated manually by con-
sidering the quality of their peaks and the metabolites
were matched with the retention times of authentic stan-
dards mixtures run in the same sequences. Library
searches were also used for identification and carried
out against accurate mass data of the metabolites in the
Human Metabolome Data Base and KEGG (Kyoto
Encyclopedia of Genes and Genomes). All metabolites
were within 3 ppm of their exact masses. Univariate
comparisons using paired t-tests were performed using
Microsoft Excel for performing paired t-tests and differ-
ences were considered significant at p < 0.05.Targeted metabolomics experiment
Skeletal muscle (quadriceps), liver and plasma were col-
lected from WT and H6PDKO littermates, frozen imme-
diately and stored until analysis at − 80 °C. Targeted
metabolomics measurements were performed in the
Metabolomics Platform of the Genome Analysis Center
of the Helmholtz Zentrum München. Frozen tissue was
homogenized using homogenization tubes containing
ceramic beads (1.4 mm diameter) and a Precellys 24
homogenizer with an integrated cooling unit. To each
mg of frozen liver or muscle tissue 3 μL of a dry ice
cooled mixture of ethanol/phosphate buffer (85/15 v/v)
were added. Samples were homogenized at − 4 °C for
three times over 20 s at 5500 rpm with 30 s pause inter-
vals to ensure constant temperatures during
homogenization. After homogenization, the samples
were centrifuged at 4 °C and 2300×g for 5 min. Either
10 μL of the tissue supernatant or 10 μL plasma were
used for the assay. Metabolite quantification was based
on FIA-ESI-MS/MS (flow injection-electrospray
ionisation-triple quadrupole mass spectrometry) and the
AbsoluteIDQ™ p150 kit (BIOCRATES Life Sciences AG,
Innsbruck, Austria). A detailed description of the tissue
preparation and the p150 assay have been published
[21]. Sample handling was performed by a Hamilton
Microlab STARTM robot (Hamilton Bonaduz AG,
Bonaduz, Switzerland) and a Ultravap nitrogen evapor-
ator (Porvair Sciences, Leatherhead, U.K.), beside stand-
ard laboratory equipment. Mass spectrometric analyses
were done on an API 4000 triple quadrupole system
(Sciex Deutschland GmbH, Darmstadt, Germany)
equipped with a 1200 Series HPLC (Agilent Technolo-
gies Deutschland GmbH, Böblingen, Germany) and a
HTC PAL auto sampler (CTC Analytics, Zwingen,
Switzerland) controlled by the software Analyst 1.5.
Compound identification and quantification were based
on multiple reaction monitoring measurements (MRM)
and appropriate internal standards. The concentrations
of plasma and tissue homogenate were reported in μM.
In total, 163 Metabolites were quantified but only acyl-
carnitines were included in the pathway analyses due to
phenotype assignment.Metabolomic set enrichment analysis
We conducted metabolite set enrichment analysis using
MetaboAnalyst [22, 23]. Significantly dysregulated me-
tabolites from the unbiased measurement in H6PDKO
compared to WT TA muscle were uploaded to Meta-
boanalyst. These were processed with the over-
representation analysis (ORA) algorithm and the meta-
bolic pathway associated metabolite library set. This ex-
amines the group of metabolites using Fisher’s exact
test, calculating the probability of seeing a particular
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of interest in the list of metabolites.
Statistical analysis
Students T-test or ANOVA statistical comparisons were
used with the Graphpad Software Inc. Prism version 5.
Data presented as mean ± SEM with statistical signifi-
cance determined as *. p < 0.05, **. p < 0.01, ***. p <
0.001. Unpaired T-Test compared treatments or geno-
types. Statistical analysis derived from real-time PCR
data was determined using dCt values throughout.
Results
Alterations in nicotinamide metabolism in H6PDKO
muscle
Global and skeletal-muscle specific knockout of H6PD
provokes a myopathy characterised by metabolic stress,
abnormal SR structure, SR stress and activation of the
unfolded protein response. We subjected Tibialis Anter-
ior (TA) skeletal muscle from WT and H6PDKO mice
to an unbiased metabolomic screen performed by LC-
MS to better understand the role H6PD plays in muscle
cell metabolism and SR redox maintenance. Those me-
tabolites significantly dysregulated in H6PDKO TA were
subject to an overrepresentation analysis algorithm com-
paring probability of occurrence against pathway associ-
ated libraries using MetaboAnalyst [22, 24]. The most
over represented pathways were those involved in nico-
tinamide and pyrimidine metabolism (Fig. 1a-b). Nico-
tinamide (NAM) generation is essential to the salvage
and biosynthesis of both NAD+ and NADH. Therefore,
changes in NAM metabolism may indicate shifts in skel-
etal muscle NAD+ availability as a result of perturbed SR
NAD(P)(H) due to H6PD deficiency. In support of this
specific metabolite changes with potential relevance to
SR redox included elevated trimethyl-L-Lysine; a con-
stituent of nuclear histone proteins and a precursor to
carnitine and fatty acid oxidation in the mitochondria,
elevated 3-Hydroxysebasicacid; associated with peroxi-
somal disorders and glycogen storage disease [25, 26]
suggestive of a defect in fatty acids synthesis and meta-
bolic defects such as medium chain acyl-CoA dehydro-
genase deficiency, and finally elevated Cis-5-
Tetradecenoylcarnitine; a marker of altered beta-
oxidation contributing to skeletal myopathy [27].
We measured NAD+/NADH levels and while no sig-
nificant change was noted in NAD+, there was a signifi-
cant 40% reduction in NADH in H6PDKO mice
(Fig. 1c-f). Maintenance of cellular NAD+ pools through
utilisation of multiple salvage and biosynthetic enzymes
is critical for NAD(P)+/NAD(P)H homeostasis (sche-
matic Fig. 1g). We therefore examined expression of the
enzymes involved in these pathways and observed
changes in the mRNAs of genes determining the NAD+associated metabolome (Fig. 1h). The most prominent
adaptation was an increase in the skeletal muscle-
restricted nicotinamide riboside kinase 2 (Nrk2) gene,
whilst the constitutively expressed salvage enzymes Nrk1
and Nampt were unchanged. Responsible for the phos-
phorylation of the NAD+ precursor nicotinamide ribo-
side (NR) into nicotinamide mononucleotide (NMN),
Nrk2 has previously been shown to be elevated in
models of muscle energy stress and cardiomyopathy
[28]. Downregulation of NAD kinase may limit gener-
ation of NADP+, and may indicate a response to prevent
NAD(H). Purine Nucleoside Phosphorylase (Pnp) (which
converts NR to NAM) and the NAD+ utilising ADP-
ribosyltransferase (Art1) were both downregulated,
which may also reflect a response to maintain NAD(H).
We further evaluated the expression of NAD+ salvage
genes prior to phenotypic presentation of myopathy in 3
week old mice. At this age Nrk2 was the only changed
transcript, being upregulated > 20-fold, suggesting this is
a primary adaptive metabolic response to H6PD defi-
ciency (Fig. 1i). Western blotting confirmed elevation of
NRK2 at the protein level and interestingly also sug-
gested upregulation of NRK1 protein, while expression
of the rate-limiting NAMPT NAD+ salvage pathway
remained unchanged (Fig. 1j-k).
H6PDKO skeletal muscle has reduced mitochondrial fatty
acid oxidative capacity and widespread changes in
acylcarnitines
Changes in NAD+/NADH turnover and availability can
impact mitochondrial function [29–31]. We therefore in-
vestigated this in permeabilised skeletal muscle fibres
from H6PDKO TA and SOL muscle using high-
resolution mitochondrial respirometry. Both TA and
SOL muscle have impaired oxygen consumption when
exposed to L-Octanoylcarnitine as an energetic sub-
strate, indicating a decreased ability to utilise substrates
for fatty acid beta-oxidation and overall respiratory cap-
acity (Fig. 2a, b). This defect was more apparent in SOL
muscle, likely representing its greater mitochondrial
density (Fig. 2b). To understand if these measurements
were a result of mitochondrial abundance we examined
mtDNA and mitochondrial respiratory complex subunit
abundance in WT and H6PDKO TA and found no dif-
ferences suggesting that the defects in respiratory cap-
acity were through impaired mitochondrial function
(Fig. 2c-d).
To further examine the basis for dysfunctional lipid
metabolism and impaired mitochondrial fatty acid oxida-
tion we conducted a targeted lipidomic analysis of
serum, liver and quadriceps from H6PDKO and WT
mice (Additional file 1: Figure S1). Liver and serum from
H6PDKO showed no significant changes in lipid profile.
However, a striking effect for elevated short-chain
Fig. 1 Altered NAD+ salvage pathway in H6PDKO muscle. a Pathway analysis of unbiased metabolomics from WT (n = 3) and H6PDKO (n = 3)
tibialis anterior (TA) skeletal muscle. b Numerical output from pathway analysis of WT and H6PD KO tibialis anterior skeletal muscle. Values shown
from pathway analysis. c-f Quantification of NAD+, NADH, total NAD(H) and ratio of NAD+/NADH in WT (n = 7) and H6PDKO (n = 6) TA muscle. g
Schematic representation of the biosynthetic generation of NAD from nicotinamide Riboside (NR) and nicotinamide (NAM) salvage, enzymes
shown in red. h qRT-PCR of NAD+ synthesis and salvage genes in WT (n = 7) and H6PDKO (n = 7) TA. i Expression of NRK2 transcript in TA muscle
of WT and H6PDKO mice at 3 and 8 weeks of age. j-k Western blotting and quantification of WT (n = 9) and H6PDKO (n = 9) TA lysates. *P < 0.05,
**P < 0.01 and ***P < 0.001
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Fig. 2 (See legend on next page.)
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Fig. 2 Impaired mitochondrial fatty acid oxidation in H6PDKO skeletal muscle. a High resolution respirometry of fatty acid oxidation in
permeabilised tibialis anterior WT (n = 3) in and H6PDKO (n = 3). b High-resolution respirometry of fatty acid oxidation using WT (n = 3) and
H6PDKO (n = 3) permeabilised. c Mitochondrial DNA (mtDNA) quantification of WT (n = 7) and H6PDKO (n = 7) muscle, measured using qRT-PCR.
d Western blots of WT and H6PDKO protein lysates (n = 9) probed for oxidative phosphorylation enzyme subunit abundance. e Acylcarnitine
species levels in WT (n = 9) and H6PDKO (n = 11) muscle measured using GC-MS/MS. Data expressed as heat-maps with log2 values representing
metabolite abundance in WT and H6PDKO. Box and Whisker plots showing significantly altered short acylcarnitines. f qRT-PCR measurement of
genes critical carnitine and fatty acids metabolism in WT (n = 7) and H6PDKO (n = 7) TA. g Schematic showing carnitine and fatty acid
metabolism between cytosol and mitochondria. h Western blots of acetylated proteins within WT (n = 6) and H6PDKO (n = 6) skeletal muscle.
*P < 0.05, **P < 0.01 and ***P < 0.001
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H6PDKO muscle tissue was seen. While free carnitine
was not significantly different, the ratio of acetyl carni-
tine to free carnitine (C2:C0) was increased, possibly sig-
nifying an increased production rate or block in use of
acetyl-CoA in H6PDKO muscle. (Fig. 2e).
Using whole genome expression array data, validated
with real-time PCR, we also found that H6PDKO muscle
have significant elevations in genes transcripts Acss2,
Far1, Acsl1, and Acaa2, which converge on acylcarnitine
and acetyl-CoA metabolism (Fig. 2f, g) [4]. Acetyl-CoA
produced during fatty acid oxidation is important to the
levels of histone acetylation and the regulation of gene
expression [32, 33]. Accumulation of mitochondrial
acetyl-CoA can lead to non-enzymatic acetylation of
multiple proteins associated with energy metabolism [34,
35]. Protein lysates from H6PDKO muscle show in-
creases in mitochondrial- Isocitrate Dehydrogenase 2
(IDH2) acetylation and nuclear histone 3 lysine 9 and ly-
sine 56 acetylation, supporting the observation of dys-
functional fatty acid metabolism (Fig. 2h).Rescuing NAD+ metabolism using nicotinamide riboside
Changes in NAD(H) homeostasis in the absence of
H6PD are associated with dysfunctional mitochondrial
fatty acid oxidation and altered protein acetylation which
is associated with an adverse metabolic phenotype (Fig. 2)
[36]. In H6PDKO muscle NAD+ levels are not signifi-
cantly lower, whereas NADH levels are 60% those of
WT. It is recognised that upregulation of the NRK path-
way is a response to metabolic stress in which there is a
drain on NAD(H) homeostasis, requiring greater input
through NR salvage [20, 28, 37]. Taking advantage of
NRK2 upregulation we attempted to enhance NAD(H)
availability through NR supplementation, which has ex-
tensively been shown as a means to augment metabolic
resilience [20, 28, 38, 39]. We also asked if increasing
NAD+ availability will reverse protein acetylation via
NAD-dependent protein deacetylases [40–43]. We sup-
plemented mice with NR (IP, 400 mg/kg twice daily over
4 consecutive days). Quantification of NAD(H) levels in
the skeletal muscle of mice receiving NR showed it to
rescue NAD(H)levels (Fig. 3a-d). Furthermore, the abilityto elevate NAD(H) was more pronounced in H6PDKO
muscle with upregulated NRK pathway activity.
We observed that after NR supplementation NRK2 ex-
pression was decreased in WT but not H6PDKO muscle.
However, NR did lead to increased expression of
NMNAT1, NAMPT and NRK1 in H6PDKO muscle,
which was not observed in WT (Fig. 3e). NAD+ boosting
did not suppress upregulation of Acyl-CoA and lipid
metabolism gene expression found in H6PDKO mice
(Fig. 3f). Protein quantification of NAMPT and NRK2
showed no change in abundance (Fig. 3g-h). Following
NR supplementation we again performed high-
resolution mitochondrial respirometry of fatty acid oxi-
dation and found no improvement in mitochondrial O2
flux in NR supplemented WT or H6PDKO muscle
(Fig. 3i-j).
To further assess the effects of augmented NAD(H)
availability we examined protein acetylation in response
to NR. Global and IDH2 acetylation were maintained at
untreated H6PDKO levels (Fig. 3k). Finally, as the
H6PDKO muscle demonstrated extensive activation of
the unfolded protein response, potentially a consequence
of altered SR NADPH/NADP+ ratio and impaired pro-
tein folding [2, 44, 45] we examined UPR markers
CHOP and the protein folding regulators ERO1a and
PDI levels and showed them to remain elevated in
H6PDKO mice despite NR supplementation and in-
creased NAD(H) availability (Fig. 3l). These data imply
that perturbed SR NAD(P)(H) as a function of H6PD de-
ficiency cannot be overcome by boosting NAD(H) avail-
ability according to this study design.
NRK2 is dispensable in H6PDKO myopathy
We also investigated the role of the NRK2 pathway in
defending muscle function in the absence of H6PD using
double knockout (DKO) mice. We reasoned DKO mice
would have an exacerbated myopathy, and may even re-
duce survival. However, DKO mice were viable, survived
at the anticipated frequency and generally indistinguish-
able from H6PDKO mice. Quantification of NAD+ levels
revealed that DKO TA has significantly decreased NAD+
levels compared to WT and to a greater degree than in
H6PD deficiency alone, with NADH and total NAD(H)
remaining depressed at H6PDKO levels (Fig. 4a-d). The
Fig. 3 (See legend on next page.)
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Fig. 3 NR supplementation, NAD+ salvage and mitochondrial function in H6PDKO muscle. a-d NAD+, NAD(H), total NAD(H) quantification and
ratio of NAD+/NADH in TA of WT and H6PDKO +/− intraperitoneal (i.p.) Nicotinamide Riboside (NR) (n = 6-9). e qRT-PCR data of genes involved in
the biosynthesis of NAD+ and salvage of NAM in WT and H6PDKO muscle +/− i.p. NR (n = 6-9). f qRT-PCR data of genes critical carnitine and fatty
acids metabolism in WT and H6PDKO muscle +/− i.p. NR (n = 6-9). g-h Western blots and quantification of the NAM salvage protein NAMPT and
the skeletal muscle specific protein NRK2 (n = 6). i High-resolution respirometry of fatty acid oxidation in permeabilised TA tissue from WT and
H6PDKO i.p NR (n = 3). j High-resolution respiration for fatty acid oxidation using WT and H6PDKO after i.p NR permeabilised SOL (n = 3). k
Western blots showing total lysine acetylation and IDH2 acetylation in WT and H6PDKO muscle +/− i.p NR. l Western blots showing ER stress
regulator CHOP and protein folding factors PDI and ERO1a in WT and H6PDKO +/− i.p NR. (n = 6-9). *P < 0.05, **P < 0.01 and ***P < 0.001
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be able to defend aspects of the NAD metabolome in
H6PD deficiency. NRK2 deficiency alone had minimal
impact in WT mice as previously reported, and likely
due to compensatory activity of the NRK1 enzyme [20].
DKO skeletal muscle exhibited myopathy and atrophy to
an equivalent degree as in H6PDKO (Fig. 4e-g). Expres-
sion of genes for NAD+ biosynthesis and Acyl-CoA me-
tabolism revealed no significant differences in the DKO
muscle compared to H6PDKO, with NRK2KO display-
ing no change compared to WT (Fig. 4h, i). Finally we
examined protein acetylation and ER stress and UPR
markers, all of which were, again, unchanged from the
levels seen in H6PDKO muscle (Fig. 4j, k).
Discussion
In this work we show that upregulation of NRK2 medi-
ated salvage of NR into NAD+ is an early adaptation to
perturbed muscle SR NAD(P)(H) homeostasis and im-
paired mitochondrial energy production in H6PD defi-
ciency. This study demonstrates that NR
supplementation can defend NAD(H) levels within
H6PD deficient muscle, but this, and ablation of the
stress responsive NRK2 pathway have little impact to
limit or worsen myopathy.
The nicotinamide riboside kinases 1 and 2 (NRKs1/2)
form part of the salvage pathway that converts NR into
NMN through to NAD+ [20]. Importantly, extracellular
NMN conversion to NAD+ is NRK dependent, requiring
it to be dephosphorylated to NR to be utilised as an
NAD+ precursor [37]. NRK1 is thought to be the domin-
ant and rate-limiting source of NR phosphorylation [20,
37] in most tissues, with NRK2 expression being limited
to skeletal and cardiac muscle tissues [37]. Upregulation
of NRK2 has been observed as a primary response to
metabolic energy stress associated with depletion of
NAD+ in genetic models of cardiomyopathy and in a
model of post-injury skeletal muscle repair [20, 28, 46].
Despite its limited expression in non-muscle tissues,
NRK2 has also been shown to be induced in axonal neu-
rons in response to damage, further supporting a role in
response to cellular damage or metabolic stress [47].
Supplementation of the vitamin B3 NR as an NAD+
precursor is well tolerated in both mice and humans andeffective in elevating muscle NAD+ levels and alleviating
aspects of the pathology seen in muscular dystrophy,
mitochondrial myopathy and ageing [48–50]. Indeed,
NR supplementation has proven to be effective in allevi-
ating cardiac defects associated with genetic cardiomy-
opathies’ [28, 46]. We report that NR was successful at
enhancing NAD(H) levels in H6PDKO muscle but un-
able to rescue physiological or molecular defects associ-
ated with the metabolic myopathy, despite elevated
NRK2 activity. It is reasonable to suggest more sustained
NR delivery, beyond the 4 day protocol used here, may
have revealed effects.
We also show that abolishing NRK2 upregulation in
H6PDKO muscle confers no discernible disadvantage,
with DKO mice indistinguishable from H6PDKO mice,
despite further deterioration in NAD+ availability. We
have previously shown that NRK1 is able to compensate
for NRK2 deficiency in terms of NAD+ salvage, and as
NRK1 protein is also upregulated in H6PDKO muscle,
may again do so in this context [20]. Also, muscle-
specific NAMPT KO mice are viable and only develop
myopathy after several months despite NAD+ levels at
90-95% those of WT mice [31]. We were unable to as-
certain the levels of NR available to the NRK2 pathway
in H6PD deficiency, and suggest that despite NRK2 ele-
vation, NR availability will be limiting, even with supple-
mentation [51].
Upregulation of NRK2 may be an early adaptive re-
sponse to metabolic stress and the need to defend
NAD+ availability. In cardiomyocytes the NRK2 gene is
activated by energy stress and NAD+ depletion through
AMP-activated protein kinase and peroxisome
proliferator-activated receptor α dependant mechanisms
[28, 52]. This may be important in exercise adaptation
as aged NRK2 KO mice show maladaptive metabolic re-
sponses to exercise in cardiac and skeletal muscle [46].
We therefore generated H6PD/NRK2 double knockout
mice to examine this further. However, loss of the stress
responsive NRK2 pathway had little impact to limit or
worsen H6PD-driven myopathy, despite further deterior-
ation in NAD(H) availability. Indeed this worsening of
NAD+ availability demonstrates the importance of the
endogenous pool of NR available to defend against situa-
tions of metabolic stress induce NAD(H) depletion.
Fig. 4 Molecular and phenotypic analysis of H6PD/NRK2 Double knockout mice. a-d NAD+, NADH, total NAD(H) and ratio of NAD+/NADH in WT,
H6PDKO, NRK2KO and DKO (H6PDKO-NRK2KO) TA muscle (n = 3-6). e-g Skeletal muscle tissue weights from WT, H6PDKO, NRK2KO and H6-NRK2
Double Knockout (DKO) (n = 3-6). h qRT-PCR of NAD+ biosynthetic gene expression in WT, H6PDKO, NRK2 KO and DKO in TA (n = 3-6). i qRT-PCR
of mitochondrial and acyl-CoA genes in TA of WT, H6PDKO, NRK2 KO and DKO (n = 3-6). j Western blots of total lysine acetylation, IDH2 and
H3K56 acetylation in WT, H6PDKO, NRK2KO and DKO muscle protein lysates (n = 3-6). k Western blots of CHOP and protein folding factors PDI
and ERO1a in WT, H6PDKO, NRK2 KO and DKO muscle lysates (n = 3-6). *P < 0.05, **P < 0.01 and ***P < 0.001
Doig et al. Skeletal Muscle            (2020) 10:5 Page 11 of 13The role NRK2 may play as a direct response to per-
turbed SR NAD(P)(H) homeostasis remains unclear
given NAD+ precursor supplementation had no impact
on acetlycarnitine metabolism or mitochondrial func-
tion. It is possible that elevated NRK2 is a directresponse to perturbed SR NAD(P)(H) homeostasis and
regulated through a mechanism distinct from that initi-
ated upon energy stress and NAD+ depletion. This no-
tion may support the concept of SR sensing and
exchange of nucleotides, nucleosides or other precursors
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have identified transporters able to carry NAD+ and
NMN across biological membranes. Importantly, NAD+
has been shown to be transported into the mitochondria
and as such increases the potential for other compart-
ments, such as the ER/SR, to transport NAD+ and asso-
ciated precursors [53]. Indeed, Slc12a8 has recently been
identified as an NMN transporter regulating intestinal
NAD+ metabolism [54]. Although an NR transporter has
been identified in yeast, there remains no conclusive evi-
dence for a dedicated NR transporter in mammalian
cells [55].
Conclusion
These data identify activation of the NRK2 pathway, and
concurrent changes in NAD+ metabolism, as an early re-
sponse to perturbations in ER/SR NAD(P)(H) homeosta-
sis as a result of H6PD deficiency in skeletal muscle.
Whether upregulation of NRK2 mediated NAD(P)(H)
salvage is a response to mitochondrial dysfunction and
energy stress, or directly to perturbation in NADP(H)
availability remains to be determined. While H6PD defi-
ciency results in a deteriorating and complex metabolic
and structural myopathy that cannot be rescued with
NAD+ supplementation, it remains an intriguing model
linking muscle SR NAD(P)(H) mediated redox and en-
ergy metabolism.
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